EU funding helping to find ocean remedies for cancerJune 11, 2004European Union funding is helping to find cancer treatments for certain deadly tumours using small marine animals. European researchers are using chemical agents extracted from a type of Caribbean sea squirt, named Ecteinascidia turbinata, to treat some tumours. The breakthrough findings will soon be published in the Marine Drugs journal. The project on "A novel marine pharmaceutical with unique mechanism of action for the treatment of cancer", has helped to establish trials in 24 EU centres across seven European countries. The project, involving Dutch, French and Spanish participants, aims to test the chemicals in treating sarcomas, a rare tumour that kills about 3,900 Europeans a year. Although sarcomas respond to chemotherapy, which shrinks the tumour's growth, a cure has not yet been found. But the discovery of the alkaloid chemical, Ecteinascidin-743 (ET-743), is a breakthrough for medical science. The chemical is used as a chemotherapeutic agent and has shown promising results in patients where other treatments have failed. It has enormous potential for treating a range of cancers, such as breast cancer. "This represents an important medical development in the treatment of certain cancers," European Research Commissioner Philippe Busquin said. "Cancer kills more than 750,000 people a year. The EU is investing up to EUR400 million in cancer research over 4 years. But our investments will only bear fruit if researchers and funding agencies across Europe work together. The project shows it is possible to overcome fragmentation in cancer research and involve private companies in developing new cancer cures." EU funding for trials could help save lives Natural resources found in the ocean, such as algae, seaweed and marine animals can help treat cancers. Early trials of the alkaloid, ET-743, or Yondelis, which is extracted from the sea squirts, have shown promising results. In May 2001 the European Agency for the Evaluation of Medicinal Products gave Yondelis "orphan status", a class of drugs targeting rare diseases, to treat sarcomas. Sea squirt chemical agents alternative to existing treatments Sarcomas are divided into two main groups, bone tumours and soft tissue sarcomas (STS). STS can only be diagnosed once tissue from the tumour is analysed under a microscope. Currently, STS are surgically removed or treated using chemotherapy and radiation therapy. A combination of treatments may be used depending on the nature of the tumour. Biological therapy, which stimulates the body's immune system to fight cancer, is still being clinically tested. ET-743 extracted from sea squirts can be used as an alternative chemotherapeutic agent to help where traditional therapies have limited impact. European co-operation means patients access new treatments sooner EU funding is helping to carry out trials for Yondelis in the 24 EU centres across the seven countries. Some 167 patients are participating in the trials to test the chemical against soft-tissue sarcomas. These trials are proving significant in developing the chemical. Yondelis may also be tested against other tumour types such as breast cancer, which kills 130 000 EU citizens a year, and with other treatments. For further information please see also: Review article "New Marine Derived Anticancer Therapeutics ? A Journey from the Sea to Clinical Trials" published in February 2004 in Marine Drugs http://www.mdpi.net/marinedrugs. The project has been coordinated with Dutch and French partners by Spanish based PharmaMar, contact: Jose Jimeno, jjimeno@pharmamar.com For the thematic priority on "life sciences, genomics and biotechnology for health" in the | |||||||||||||||||||||
|
Related Cancer Current Events and Cancer News Articles Deaths from lung cancer could be reduced by better policies to control indoor radon About 1100 people each year die in the UK from lung cancer related to indoor radon, but current government protection policies focus mainly on the small number of homes with high radon levels and neglect the 95% of radon related deaths caused by lower levels of radon, according to a study published on bmj.com today. Protein's essential role in repairing damaged cells revealed University of Michigan researchers have discovered that a key protein in cells plays a critical role in not one, but two processes affecting the development of cancer. Interpretation Time for Screening Digital Mammograms: Is it Efficient? Digital mammograms take longer to interpret than film-screen mammograms, according to a study performed at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. Scientists can now differentiate between healthy cells and cancer cells One of the current handicaps of cancer treatments is the difficulty of aiming these treatments at destroying malignant cells without killing healthy cells in the process. Team finds breast cancer gene linked to disease spread A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death. New hope for cancer comes straight from the heart Digitalis-based drugs like digoxin have been used for centuries to treat patients with irregular heart rhythms and heart failure and are still in use today. In the Dec. 16 issue of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine now report that this same class of drugs may hold new promise as a treatment for cancer. Cell Biologists Identify New Tumor Suppressor for Lung Cancer Cancer and cell biology experts at the University of Cincinnati (UC) have identified a new tumor suppressor that may help scientists develop more targeted drug therapies to combat lung cancer. Errors involving medications common in outpatient cancer treatment Seven percent of adults and 19 percent of children taking chemotherapy drugs in outpatient clinics or at home were given the wrong dose or experienced other mistakes involving their medications. Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract. In lung cancer, silencing one crucial gene disrupts normal functioning of genome While examining patterns of DNA modification in lung cancer, a team of international researchers has discovered what they say is a surprising new mechanism. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||